Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells

Chembiochem. 2022 Sep 5;23(17):e202200196. doi: 10.1002/cbic.202200196. Epub 2022 Jul 13.

Abstract

Targeting of glucagon-like peptide 1 receptor (GLP-1R), expressed on the surface of pancreatic β-cells, is of great interest for the development of advanced therapies for diabetes and diagnostics for insulinoma. We report the conjugation of exendin-4 (Ex-4), an approved drug to treat type 2 diabetes, to poly-γ-glutamic acid (γ-PGA) to obtain more stable and effective GLP-1R ligands. Exendin-4 modified at Lysine-27 with PEG4-maleimide was conjugated to γ-PGA functionalized with furan, in different molar ratios, exploiting a chemoselective Diels-Alder cycloaddition. The γ-PGA presenting the highest number of conjugated Ex-4 molecules (average 120 per polymeric chain) showed a double affinity towards GLP-1R with respect to exendin per se, paving the way to improved therapeutic and diagnostic applications.

Keywords: GLP-1R; beta-cell targeting; diabetes; exendin-4; pancreatic tumor; poly-gamma-glutamic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Exenatide / chemistry
  • Glucagon-Like Peptide-1 Receptor
  • Glutamic Acid
  • Humans
  • Pancreatic Neoplasms*
  • Peptides / chemistry
  • Polyglutamic Acid / analogs & derivatives
  • Radiopharmaceuticals / chemistry

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Peptides
  • Radiopharmaceuticals
  • poly(gamma-glutamic acid)
  • Polyglutamic Acid
  • Glutamic Acid
  • Exenatide